3 completed, 3 recruiting, 3 unknown, 2 not yet recruiting. 14 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 3, Recruiting 3, Unknown 3, Not yet recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 8 | Recruiting 3, Unknown 3, Completed 1, Not yet recruiting 1 |
Follow NSCLC Stage IV: new trials by email Literature Review of NSCLC Stage IV trials Research Report on NSCLC Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC Glecirasib, Ivonescimab - NSCLC Stage IV, KRAS G12C | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2026-03-01 | 2026-01-14 |
| HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC HY1272 - NSCLC Stage IV | Phase 1 | Not yet recruiting | Newsoara Biopharma Co., Ltd. | 40 | 2024-12-01 | 2024-01-23 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer MYTX-011 - NSCLC, NSCLC Stage IV | Phase 1 | Terminated | Mythic Therapeutics | 227 | 2023-03-23 | 2025-12-16 |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) Cadonilimab, Anlotinib, Docetaxel - NSCLC Stage IV, NSCLC Stage IIIB | Phase 1 / Phase 2 | Unknown | Shanghai Chest Hospital | 50 | 2023-02-16 | 2024-06-17 |
| A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion - Malignant Pleural Effusions, NSCLC Stage IV | Phase 1 / Phase 2 | Recruiting | Wuhan YZY Biopharma Co., Ltd. | 116 | 2022-09-30 | 2026-07-08 |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI - NSCLC Stage IV, Melanoma Stage IV | Phase 1 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 45 | 2022-06-29 | 2025-07-30 |
| Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC Atezolizumab - NSCLC Stage IV, NSCLC, Recurrent | Phase 1 / Phase 2 | Recruiting | University of Kansas Medical Center | 25 | 2022-05-18 | 2026-01-28 |
| A Study to Investigate LYL797 in Adults With Solid Tumors LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Terminated | Lyell Immunopharma, Inc. | 57 | 2022-03-29 | 2025-07-01 |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC Nivolumab Combined with Anlotinib - NSCLC Stage IV, Checkpoint Inhibitor | Phase 1 / Phase 2 | Completed | Shanghai Chest Hospital | 21 | 2020-11-02 | 2022-06-28 |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC Fecal Microbial Transplantation by capsules - Melanoma Stage IV, Unresectable Melanoma | Phase 1 / Phase 2 | Unknown | Ella Therapeutics Ltd | 42 | 2020-11-01 | 2021-08-16 |
| Neo-MASCT Immunotherapy for Advanced NSCLC. Neo-MASCT - NSCLC Stage IV | Phase 1 / Phase 2 | Unknown | The First People's Hospital of Lianyungang | 20 | 2017-08-01 | 2017-07-05 |
| Phase I Study of SPH1188-11 in NSCLC SPH1188-11 - NSCLC Stage IIIB, NSCLC Stage IV | Phase 1 | Withdrawn | Shanghai Pharmaceuticals Holding Co., Ltd | 2017-07-21 | 2021-11-08 | |
| Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer Immune Killer Cells (IKC) - NSCLC Stage IIIB, NSCLC Stage IV | Phase 1 | Completed | Ivy Life Sciences, Co., Ltd | 20 | 2005-04-26 | 2018-05-09 |
Carcinoma, Non-Small-Cell Lung (14) · Lung Neoplasms (2) · Melanoma (2) · Recurrence (2) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pleural Effusion, Malignant (1) · Triple Negative Breast Neoplasms (1)
Bronchial Neoplasms (14) · Carcinoma, Bronchogenic (14) · Lung Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Respiratory Tract Diseases (14) · Respiratory Tract Neoplasms (14) · Thoracic Neoplasms (14) · Lung Neoplasms (12) · Neoplasms by Histologic Type (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Disease Attributes (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2)
anlotinib (2) · Docetaxel (1) · Nivolumab (1) · Protein Subunit Vaccines (1) · atezolizumab (1) · pirfenidone (1)
Shanghai Chest Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Ella Therapeutics Ltd (1) · Ivy Life Sciences, Co., Ltd (1) · Lyell Immunopharma, Inc. (1) · Mythic Therapeutics (1) · Newsoara Biopharma Co., Ltd. (1) · Shanghai Pharmaceuticals Holding Co., Ltd (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The First People's Hospital of Lianyungang (1) · University of Kansas Medical Center (1) · Wuhan YZY Biopharma Co., Ltd. (1)
China (5) · United States (4) · Australia (1) · Canada (1) · France (1) · Israel (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Arielle Elkrief, MD (1) · Baohui Han, M.D (1) · Chao Huang, MD (1) · Guy Ben-Betzalel, MD (1) · Hannah Chen (1) · Jackie Walling, MBChB, PhD (1) · Jianya Zhou, M.D (1) · Jing Wang, M.D (1) · JunNing Cao, Master (1) · Kuo-Ching Yang, MD, PhD (1) · Ting Wu, MD MSc (1) · Vincent Lam, MD (1) · Yiping Zhang (1) · Zhengbo Song (1) · Zhuang Yu, M.D (1)